{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:35:00Z","timestamp":1785803700224,"version":"3.56.0"},"reference-count":50,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Italian Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","award":["FFC#3\/2018"],"award-info":[{"award-number":["FFC#3\/2018"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cystic fibrosis (CF) is one of the most frequent lethal autosomal recessive diseases affecting the Caucasian population. It is caused by loss of function variants of the cystic fibrosis transmembrane conductance regulator (CFTR), a membrane protein located on the apical side of epithelial cells. The most prevalent CF-causing mutation, the deletion of phenylalanine at position 508 (F508del), is characterized by folding and trafficking defects, resulting in the decreased functional expression of the protein on the plasma membrane. Two classes of small-molecule modulators, termed potentiators and correctors, respectively, have been developed to rescue either the gating or the cellular processing of defective F508del CFTR. Kaftrio, a next-generation triple-combination drug, consisting of the potentiator ivacaftor (VX770) and the two correctors tezacaftor (VX661) and elexacaftor (VX445), has been demonstrated to be a life-changing therapeutic modality for the majority of people with CF worldwide. While the mechanism of action of VX770 and VX661 is almost known, the precise mechanism of action and binding site of VX445 have not been conclusively determined. We investigated the activity of VX445 on mutant F508del to identify the protein domains whose expression is mostly affected by this corrector and to disclose its mechanisms of action. Our biochemical analyses revealed that VX445 specifically improves the expression and the maturation of MSD2, heterologously expressed in HEK 293 cells, and confirmed that its effect on the functional expression of defective F508del CFTR is additive either with type I or type II CFTR correctors. We are confident that our study will help to make a step forward in the comprehension of the etiopathology of the CF disease, as well as to give new information for the development and testing of combinations of even more effective correctors able to target mutation-specific defects of the CFTR protein.<\/jats:p>","DOI":"10.3390\/ijms241612838","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T09:57:02Z","timestamp":1692179822000},"page":"12838","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2"],"prefix":"10.3390","volume":"24","author":[{"given":"Roberta","family":"Bongiorno","sequence":"first","affiliation":[{"name":"Istituto di Biofisica, CNR, Via De Marini, 6, 16149 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ludovico","sequence":"additional","affiliation":[{"name":"Istituto di Biofisica, CNR, Via De Marini, 6, 16149 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1287-6176","authenticated-orcid":false,"given":"Oscar","family":"Moran","sequence":"additional","affiliation":[{"name":"Istituto di Biofisica, CNR, Via De Marini, 6, 16149 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8764-2468","authenticated-orcid":false,"given":"Debora","family":"Baroni","sequence":"additional","affiliation":[{"name":"Istituto di Biofisica, CNR, Via De Marini, 6, 16149 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: Genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: A clinical view","volume":"74","author":"Castellani","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: From molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","article-title":"Molecular Structure of the Human CFTR Ion Channel","volume":"169","author":"Liu","year":"2017","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fphar.2012.00201","article-title":"Mechanisms of CFTR Folding at the Endoplasmic Reticulum","volume":"3","author":"Kim","year":"2012","journal-title":"Front. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-016-2387-7","article-title":"From the endoplasmic reticulum to the plasma membrane: Mechanisms of CFTR folding and trafficking","volume":"74","author":"Farinha","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"25710","DOI":"10.1016\/S0021-9258(18)47306-1","article-title":"Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins","volume":"269","author":"Ward","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","article-title":"Degradation of CFTR by the ubiquitin-proteasome pathway","volume":"83","author":"Ward","year":"1995","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cell.2006.06.041","article-title":"Sequential Quality-Control Checkpoints Triage Misfolded Cystic Fibrosis Transmembrane Conductance Regulator","volume":"126","author":"Younger","year":"2006","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1523-1755.2000.00921.x","article-title":"Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator","volume":"57","author":"Skach","year":"2000","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1128\/MCB.25.12.5242-5252.2005","article-title":"Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin","volume":"25","author":"Farinha","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","article-title":"Multiple proteolytic systems, including the proteasome, contribute to CFTR processing","volume":"83","author":"Jensen","year":"1995","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"Zolin","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","article-title":"Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis","volume":"63","author":"Cheng","year":"1990","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molmed.2011.10.003","article-title":"CFTR: Folding, misfolding and correcting the \u0394F508 conformational defect","volume":"18","author":"Lukacs","year":"2012","journal-title":"Trends Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/354526a0","article-title":"Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation","volume":"354","author":"Dalemans","year":"1991","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1073\/pnas.0800254105","article-title":"Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function","volume":"105","author":"Serohijos","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cell.2011.11.023","article-title":"Requirements for efficient correction of \u0394F508 CFTR revealed by analyses of evolved sequences","volume":"148","author":"Mendoza","year":"2012","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1191542","article-title":"Peripheral protein quality control removes unfolded CFTR from the plasma membrane","volume":"329","author":"Okiyoneda","year":"2010","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36762","DOI":"10.1074\/jbc.M508944200","article-title":"The short apical membrane half-life of rescued \u0394F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of \u0394F508-CFTR in polarized human airway epithelial cells","volume":"280","author":"Brown","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pharmthera.2016.11.009","article-title":"New horizons for cystic fibrosis treatment","volume":"170","author":"Fajac","year":"2017","journal-title":"Pharmacol Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores \u2206F508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/emmm.201302699","article-title":"Discovery of novel potent DeltaF508-CFTR correctors that target the nucleotide binding domain","volume":"5","author":"Odolczyk","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"VX-809 TRAFFIC and TRANSPORT Study Groups. Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: A pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VXS VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Almughem, F.A., Aldossary, A.M., Tawfik, E.A., Alomary, M.N., Alharbi, W.S., Alshahrani, M.Y., and Alshehri, A.A. (2020). Cystic fibrosis: Overview of the current development trends and innovative therapeutic strategies. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070616"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VXS VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.aaw7611","article-title":"Structural identification of a hotspot on CFTR for potentiation","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bcp.2013.06.028","article-title":"Corrector VX-809 stabilizes the first transmembrane domain of CFTR","volume":"86","author":"Loo","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Amico, G., Brandas, C., Moran, O., and Baroni, D. (2019). Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215463"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Capurro, V., Tomati, V., Sondo, E., Renda, M., Borrelli, A., Pastorino, C., Guidone, D., Venturini, A., Giraudo, A., and Mandrup Bertozzi, S. (2021). Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105262"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gramegna, A., Contarini, M., Aliberti, S., Casciaro, R., Blasi, F., and Castellani, C. (2020). From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165882"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2002774","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor + tezacaftor + ivacaftor mediated in part by the dual activities of Elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"Eur. Respir."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1021\/bi4008758","article-title":"Bithiazole correctors rescue CFTR mutants by two different mechanisms","volume":"52","author":"Loo","year":"2013","journal-title":"Biochemistry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1091\/mbc.e08-09-0929","article-title":"Mechanisms for rescue of correctable folding defects in CFTRDelta F508","volume":"20","author":"Grove","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Brandas, C., Ludovico, A., Parodi, A., Moran, O., Millo, E., Cichero, E., and Baroni, D. (2021). NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis. Biomolecules, 11.","DOI":"10.3390\/biom11101417"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"19810","DOI":"10.1038\/s41598-021-99184-1","article-title":"Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment","volume":"11","author":"Shaughnessy","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0014-5793(01)02561-3","article-title":"Green fluorescent protein-based halide indicators with improved chloride and iodide affinities","volume":"499","author":"Galietta","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"C1734","DOI":"10.1152\/ajpcell.2001.281.5.C1734","article-title":"Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists","volume":"281","author":"Galietta","year":"2001","journal-title":"Am. J. Physiol. Cell Physiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/16\/12838\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:34:33Z","timestamp":1760128473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/16\/12838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":50,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241612838"],"URL":"https:\/\/doi.org\/10.3390\/ijms241612838","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]}}}